DEC 23, 2019 8:40 AM PST

Novel Drug for Treating Insomnia

WRITTEN BY: Nouran Amin

The U.S. Food and Drug Administration (FDA) has approved DAYVIGO™ (lemborexant) in 5 mg and 10 mg for the treatment of insomnia among adult patients with insomnia. Insomnia is a difficult sleeping condition characterized by the inability to sleep or maintain sleep.

Learn more about insomnia:

Approval for DAYVIGO comes after two randomized and double-blined Phase 3 studies that evaluated the efficacy of the drug in comparison to the placebo. One study noted results for one month and the other study continued the comparison for six months. Despite good results, FDA encourages DAYVIGO to be placed under the controlled substances and such is currently being evaluated by the U.S. Drug Enforcement Administration (DEA) before being commercially available.

"We believe the approval of DAYVIGO is particularly exciting because it is the first FDA-approved medication to report safety data over a 12-month period along with sleep onset and sleep maintenance efficacy data over a six-month period in a pivotal clinical study," said Lynn Kramer, MD, Chief Clinical Officer, Neurology Business Group, Eisai Pharmaceutical. "We look forward to making this new therapeutic option available to the millions of patients who suffer with insomnia."

DAYVIGO was developed by the pharmaceutical drug company, Eisai.

"Insomnia disorder is a chronic condition that has a variety of potential negative impacts and long-term consequences for health and well-being,"2 said Russell Rosenberg, PhD, D.ABSM, a principal investigator in the DAYVIGO clinical studies and former Chairman of the Board of the National Sleep Foundation. "The clinical trials provide evidence that DAYVIGO may improve patients' ability to fall asleep and stay asleep."

In both studies, the most commonly reported side-effects that led to discontinuation was because somnolence and nightmares. In addition, the effects of DAYVIGO at the beginning of treatment were generally the same as the endpoint.

The drug was not associated with rebound insomnia following discontinuation or any withdrawal effects. However, DAYVIGO was associated with dose-dependent worsening effects on attention and memory compared to the placebo.

"DAYVIGO is an important addition to Eisai's rapidly growing neurology portfolio and underscores our leadership in neuroscience," said Ivan Cheung, Chairman and CEO, Eisai Inc. and Global President, Neurology Business Group, Eisai Co., Ltd. "Our commitment to patients and their families drives our relentless pursuit of innovative healthcare solutions."

Source: FDA

About the Author
  • Nouran earned her BS and MS in Biology at IUPUI and currently shares her love of science by teaching. She enjoys writing on various topics as well including science & medicine, global health, and conservation biology. She hopes through her writing she can make science more engaging and communicable to the general public.
You May Also Like
NOV 10, 2019
Drug Discovery & Development
NOV 10, 2019
Promising Results for New Vaccine Against Dengue Fever
Dengue fever is an illness transmitted by mosquito bites. Affecting around 390 million people per year, if left untreated, its mortality rate is 20%. Altho...
NOV 25, 2019
Technology
NOV 25, 2019
How artificial intelligence (AI) is improving immunotherapy
Researchers at Case Western Reserve University’s digital imaging lab are pioneering the use of Artificial Intelligence (AI) to predict the efficacy o...
NOV 25, 2019
Drug Discovery & Development
NOV 25, 2019
Discovery of mechanism behind Alexander disease may lead to enhanced drug development
Researchers have long known that the cause behind Alexander disease is a genetic culprit—mainly a mutation leading to the production of a defective p...
DEC 02, 2019
Drug Discovery & Development
DEC 02, 2019
New Ultrasound Treatment for Parkinson's Tremors
A non-invasive ultrasound procedure may provide lasting relief from tremors in people with Parkinson’s disease (PD) and essential tremor (ET), accord...
DEC 16, 2019
Drug Discovery & Development
DEC 16, 2019
Drug Targets Against The Nipah Virus
The Nipah virus, first identified in 1998 and is transmitted from pigs and bats, has resulted in a high mortality rate killing more than half of all infect...
DEC 20, 2019
Drug Discovery & Development
DEC 20, 2019
Drug Repurposing May Provide Hope for Deadly Childhood Seizure Disorder
The life-threatening and treatment-resistant seizure disorder among children known as the ‘Dravet Syndrome’ may soon have new safe and effectiv...
Loading Comments...